Skip to Content

Optimizing recombinant protein production for domain antibodies: proof-of-concept

Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeutics on the nanometer scale can cross the blood-brain barrier and enter the parenchyma. Developing protein-based therapeutics is attractive for a number of reasons, yet, the production pipeline for high yield and consistent bioactive recombinant proteins is a major obstacle. This project directly addresses this issue and evaluates the potential to use Brevibacillus host to produce biologically active domain antibody proteins for future use in nanoparticle therapeutics.

Symposium Participant

Portrait of Glenna Embrador

Glenna Embrador

Project Details

Symposium Date: Fall 2018

Research Theme: Health

Presentation Type: FURI

Faculty Mentors

  • Barbara Smith